Navigation Links
Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
Date:6/15/2009

on of such activities, the Company now expects its IND filing to occur within approximately six months of the previously anticipated date of July 31, 2009. The success of upcoming program efforts, including the remaining GMP scale-up production activities, the outcome of its upcoming pre-IND meeting and the outcome of the remaining non-clinical pharmacology and toxicology studies will ultimately determine the timing of Helix's Phase I/II IND/CTA filings.

Topical Interferon Alpha-2b Product Development Update - Cervical Displasia Indication ("LSIL")

During the quarter, Helix received regulatory approval to conduct its European Phase II pharmacokinetic study in human subjects prior to initiating its planned Phase IIb/III trials, and enrollment in the study is actively underway.

In parallel with its clinical progress, Helix has continued to advance its GMP production activities in anticipation of the Phase IIb and III trials in the United States and Europe respectively. Although all activities in preparation for the planned Phase IIb/III trials are progressing, the Company has experienced some delays associated with the GMP manufacturing scale-up program and in initiating the human pharmacokinetic study.

Helix is preparing to conduct a pre-IND meeting with the FDA to confirm its pivotal efficacy trial plans. Helix has submitted its formal meeting request, and is awaiting a reply from the authority confirming their timing availability. The outcome of this meeting along with the success of Helix's remaining GMP manufacturing scale-up and human pharmacokinetic study activities, will determine the timing of Helix's U.S. IND filing which was previously anticipated by July 31, 2009 but is now not expected before the end of Helix's fiscal 2010 first quarter ending October 31, 2009. The new expected timing of filing the confirmatory European Phase III Clinical Trial Application has not yet been establish
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
(Date:7/10/2014)... Calabasas, CA (PRWEB) July 10, 2014 ... academic institutions and professional associations, addressed the challenges of ... & Medical Device Industries” through strategic sourcing. Describing the ... ) with the Supply Chain Management Institute ( SCMI) ... the event on June 24 at the Kroc Institute ...
(Date:7/10/2014)... PROVO, Utah , July 10, 2014 ... genome annotation and interpretation, today announced an ... sequencing (NGS) analytics for Lineagen,s NextStep Dx ... evaluation of neurodevelopmental and neurological disorders, currently ... chromosomal microarray (CMA) testing service used by ...
(Date:7/10/2014)... help in the fight against terrorism with the creation ... explosives with the use of light and special glass ... Actuators B: Chemical , the researchers describe a novel ... as low as 6.3 ppm (parts per million). It ... , "Traditionally explosives detection has involved looking for metals ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Detecting trace amounts of explosives with light 2
... and Jack Ballantyne, Forensic Biochemistry/Genetics Professor at University of ... join ... GenVault Corporation today,announces that two leading industry experts, ... its Scientific Advisory Board. Dr.,Lai-Goldman is currently the Chief ...
... primer, now in its 3rd edition., ... the third,edition of Building Biotechnology, the definitive ... business courses. This new,edition adds over 100 ... new,and updated figures and tables, and many ...
... -- Record consolidated revenues of $14.9 million -- Record ... $2.3 million - 49% growth ... credit facility - expands capital resources, -- Reported MIS procedure times of 60 minutes and hospital ... days or ...
Cached Biology Technology:GenVault Expands Scientific Advisory Board 2GenVault Expands Scientific Advisory Board 3New Book on the Business of Biotechnology 2AtriCure Reports Record Second Quarter 2008 Financial Results 2AtriCure Reports Record Second Quarter 2008 Financial Results 3AtriCure Reports Record Second Quarter 2008 Financial Results 4AtriCure Reports Record Second Quarter 2008 Financial Results 5AtriCure Reports Record Second Quarter 2008 Financial Results 6AtriCure Reports Record Second Quarter 2008 Financial Results 7AtriCure Reports Record Second Quarter 2008 Financial Results 8
(Date:7/11/2014)... division of the striatum is also involved in ... of substance P in the striatal marginal division ... his team, College of Biophotonics, South China Normal ... P receptor, neurokinin 1 was highly expressed in ... rats. Unilateral or bilateral injection of an antisense ...
(Date:7/11/2014)... Brazil- In the brains of all vertebrates, information ... an electric or chemical signal to be passed ... which are the most abundant type of synapse, ... is crucial for learning, memory, perception and cognition, ... critical for brain function. For instance, every ...
(Date:7/10/2014)... 2014 Smart technology emphasis grows in ... improved security: NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. (NASDAQ: ... Apple Inc. (NASDAQ: AAPL ), Visa Inc. (NYSE: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on ... second series of 30 second spots on CNBC for its ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5
... Mass.--MIT engineers and colleagues have built a new tissue ... transplanted into the knees and other joints. The ... injuries and other cartilage damage, such as arthritis, says ... Science and Engineering and co-leader of the research team ...
... of Medical Genetics (ACMG) has issued a new Position ... Spots. In May 2006, ACMG recommended that all newborns ... Tremendous progress has been made in,implementing broader and more ... thousands of babies, lives have been saved or have ...
... of how the elevated glucose levels that occur in ... for blocking the destruction, Medical College of Georgia researchers ... vessels to relax resulted from increased activity of a ... Dr. Rita C.Tostes, physiologist in the MCG School of ...
Cached Biology News:MIT: New tissue scaffold regrows cartilage and bone 2American College of Medical Genetics affirms importance of newborn screening dried blood spots 2New evidence of how high glucose damages blood vessels could lead to new treatments 2
... is formulated specifically for Alkaline Phosphatase conjugates. ... of activity for both the enzyme and ... dilution. This product has been chemically ... customer a longer shelf life, resistance to ...
... Mouse monoclonal [3D12] to Lambda Free ... Mixture of light chains of human ... for independent constantly expressed epitope of ... dimer forms of free lambda chains ...
... The SDSaway reagent is a valuable ... samples. The presence of SDS in ... the tightly bound SDS-protein complex, inhibits enzymatic ... and presents as a contaminant in mass ...
... ALH 4000 workstation is the simplest, easiest-to-use ... introduce automated liquid handling capabilities,into their labs, ... to support routine applications on a separate ... walk-away automation even when you have ...
Biology Products: